Stock Analiz

Cardlytics, Inc. CDLX

Computer Software: Programming Data Processing · IPO 2018 · data as of November 13, 2026

$1.34Market cap $8M
Open the interactive analysis →

Cardlytics, Inc. (CDLX) is a technology company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $176M and net income of -$37M, a net margin of -20.8%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is financial health (0/5).

Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -53%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 14% above the current price.

About Cardlytics

Cardlytics is listed in the US and classified in computer software: programming data processing, IPO year 2018. Revenue went from $113M in 2016 to $233M in 2025, growth of about 8.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 59% over three years (dilution for shareholders). It spends 17% of revenue on research and development.

Score: 0.8 / 5

Value1/5
Future growth2/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.0
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-88.1%
Shareholder yield0.0%
Intrinsic value vs. price+14%

Growth and quality

Revenue growth (1 yr)-16.2%
Revenue growth (5 yrs, per year)4.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-72.0%
ROIC (5-yr avg.)-53.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$176M$233M$278M$309M$299M$267M$187M$210M$151M$130M$113M
Net income-$37M-$103M-$189M-$135M-$465M-$129M-$55M-$17M-$53M-$20M-$76M
Free cash flow-$7M$9M-$10M-$852000-$55M-$42M-$13M$3M-$25M-$23M-$34M
EPS (diluted)—$-1.95$-3.91$-3.69$-13.92$-3.99$-2.04$-0.72$-2.79$-7.86$-32.48
Net margin-20.8%-44.4%-68.0%-43.6%-155.8%-48.1%-29.6%-8.2%-35.2%-15.1%-67.1%
ROIC—-47.9%-65.9%-36.3%-102.1%-13.0%-15.7%-12.1%-41.4%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Cardlytics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 14% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Cardlytics pay a dividend?

Not currently.

Is Cardlytics a good stock to buy?

We do not give buy or sell advice. Cardlytics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.